Board Certification and Academic Information
| Academic Departments |
Internal Medicine - Instructor (Clinical)
|
| Academic Divisions |
Hematology/BMT
|
| Board Certification |
American Board of Allergy & Immunology
American Board of Internal Medicine
American Board of Internal Medicine (Sub: Medical Oncology)
|
Academic Office Locations
| Academic Office Phone Number |
Academic Office Address |
| (801) 433-4334 |
Huntsman Cancer Institute
Hematology and Hematologic Malignancies
2000 Circle of Hope
Salt Lake City, UT 84112 |
Academic Bio
Ahmad S. Halwani, M.D. is a Clinical Instructor in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah School of Medicine. Dr. Halwani also has an appointment at the George E. Whalen Salt Lake City Veteran's Affairs Medical Center, where he started a Leukemia-Lymphoma clinic, the Salt Lake City VA's first subspecialty oncology clinic. Specializing in the treatment of blood related cancers such as lymphoma and leukemia, his main clinical operation is at the University of Utah Huntsman Cancer Institute Clinic 2B. He is an investigator at the Huntsman Cancer Institute and a member of the Experimental Therapeutics program.
Dr. Halwani's research interests include immunotherapy for hematologic malignancies, as well as understanding the interactions between the immune system and cancer. Immunotherapy for treatment of cancer is a rapidly expanding field. Novel antibodies target various cancer associated antigens. In addition, new immunomodulators target the microenvironment around the cancer cells. As the understanding of regulatory immune mechanisms evolves, T-cell costimulation inhibition is an exciting new modality that has shown exciting results in treatment of multiple cancers. As a clinical and translational investigator, Dr. Halwani’s research focuses on design and implementation of clinical trials that bring recent advances in immunotherapy from bench to bedside. He is principle investigator on a number of clinical trials that focus on treatment of hematologic malignancies with immune therapies, including novel antibodies with augmented mechanisms of action, antibody-drug conjugates, and T-cell costimulation inhibitors. His clincal trial portfolio ranges the entire spectrum of clinical trials, from phase I to randomized phase III trials.
He received his B.S. in Biology, with High Distinction, from the American University of Beirut in Lebanon, followed by his medical degree also at the American University of Beirut. Dr. Halwani next completed his residency in Internal Medicine at the University of Iowa Hospitals and Clinics, then two consecutive Fellowships, also at Iowa: in Allergy and Immunology and then in Medical Oncology. Dr. Halwani is board certified in Internal Medicine, Medical Oncology, and in Allergy and Immunology.
